Drug Discovery and Human African Trypanosomiasis: A Disease Less Neglected?
Citations Over TimeTop 10% of 2013 papers
Abstract
Human African trypanosomiasis (HAT) has been neglected for a long time. The most recent drug to treat this disease, eflornithine, was approved by the US FDA in 2000. Current treatments exhibit numerous problematic side effects and are often ineffective against the debilitating CNS resident stage of the disease. Fortunately, several partnerships and initiatives have been formed over the last 20 years in an effort to eradicate HAT, along with a number of other neglected diseases. This has led to an increasing number of foundations and research institutions that are currently working on the development of new drugs for HAT and tools with which to diagnose and treat patients. New biochemical pathways as therapeutic targets are emerging, accompanied by increasing numbers of new antitrypanosomal compound classes. The future looks promising that this collaborative approach will facilitate eagerly awaited breakthroughs in the treatment of HAT.
Related Papers
- → What constitutes a neglected tropical disease?(2020)171 cited
- → “Rapid impact” 10 years after: The first “decade” (2006–2016) of integrated neglected tropical disease control(2018)38 cited
- → Current chemotherapy of human African trypanosomiasis(2003)116 cited
- [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].(1989)
- → Neglected Tropical Disease (NTDs)(2024)